Shanghai Novamab Biopharmaceuticals Co., Ltd.

Primary study objective: To evaluate the safety and tolerability of LQ043H single-domain antibody nebulized solution in healthy subjects with increasing doses and single nebulized inhalation. Secondary study objective: To evaluate the pharmacokinetic and immunogenic characteristics of LQ043H single-domain antibody nebulized solution in healthy subjects with increasing doses and single nebulized inhalation.

Primary objectives: To evaluate the tolerability and safety of LQ036 after single and multiple administrations in healthy Chinese subjects, and to provide a basis for subsequent clinical trials. Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of LQ036 after single and multiple administrations in healthy Chinese subjects; (2) To evaluate the pharmacodynamic characteristics of LQ036 after single and multiple administrations in healthy Chinese subjects; (3) To evaluate the immunogenicity of LQ036 after single and multiple administrations in healthy Chinese subjects.